Adaptive Biotechnologies has announced it has completed a series C financing round and completed a newly created series D round of financing with a $105 million investment from Viking Global Investors.
Adaptive Biotechnologies, based in Seattle, Wash., is an immunosequencing diagnostics company with a focus in oncology.
Viking Global Investors, based in Greenwich, Conn., is a global investment firm managing more than $20 billion in capital across long-short equity and long-only strategies.
The new funding for Adaptive Biotechnologies will be initially allocated to the expansion of the company's immunoSEQ research platform through the launch of a research use only kit in the third quarter of 2014.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.